Cwm LLC Acquires 6,659 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Cwm LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 26.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,924 shares of the medical equipment provider’s stock after purchasing an additional 6,659 shares during the quarter. Cwm LLC’s holdings in Intuitive Surgical were worth $10,770,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ISRG. Vanguard Group Inc. grew its holdings in Intuitive Surgical by 0.7% during the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock valued at $8,730,184,000 after purchasing an additional 196,316 shares during the period. Jennison Associates LLC grew its stake in shares of Intuitive Surgical by 6.4% during the 3rd quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock valued at $1,340,205,000 after acquiring an additional 274,692 shares during the period. Invesco Ltd. increased its holdings in Intuitive Surgical by 6.6% in the 3rd quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock worth $1,096,231,000 after acquiring an additional 232,205 shares in the last quarter. Northern Trust Corp raised its stake in Intuitive Surgical by 3.4% during the 3rd quarter. Northern Trust Corp now owns 3,514,421 shares of the medical equipment provider’s stock worth $1,027,230,000 after acquiring an additional 115,059 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Intuitive Surgical by 0.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,030,415 shares of the medical equipment provider’s stock worth $593,470,000 after acquiring an additional 17,477 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on ISRG shares. Jefferies Financial Group increased their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday. Piper Sandler increased their price target on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday. Robert W. Baird decreased their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research note on Friday. Truist Financial raised their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. Finally, Royal Bank of Canada boosted their target price on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $396.17.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $368.93 on Tuesday. The firm has a market capitalization of $130.77 billion, a P/E ratio of 66.59, a price-to-earnings-growth ratio of 5.69 and a beta of 1.36. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The company’s 50-day moving average is $386.57 and its 200 day moving average is $344.41.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the previous year, the business earned $1.00 EPS. Intuitive Surgical’s revenue was up 11.5% compared to the same quarter last year. Research analysts anticipate that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In other news, VP Marshall Mohr sold 108,790 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the firm’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now directly owns 26,877 shares in the company, valued at approximately $10,349,795.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $370.20, for a total value of $740,400.00. Following the completion of the sale, the director now owns 25,319 shares of the company’s stock, valued at $9,373,093.80. The disclosure for this sale can be found here. Insiders sold a total of 248,418 shares of company stock valued at $95,927,097 in the last three months. Company insiders own 0.80% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.